Login Register Cart 0
Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

The Course of COVID-19 in Four Patients with HIV During the Pandemic

Author(s): Melda Turken*, Hividar Altan, Sabri Atalay and Sukran Kose

Volume 19, Issue 3, 2021

Published on: 01 December, 2020

Page: [286 - 291] Pages: 6

DOI: 10.2174/1570162X18666201201093540

Price: $65

Abstract

Background: The clinical spectrum of SARS-CoV-2 infection may vary from simple colds to a severe acute respiratory syndrome, metabolic acidosis, septic shock, and multiple organ failure. Current evidence indicates that the risk of severe illness increases with age, in the male sex, and with certain chronic medical problems. Many people living with HIV have other conditions that increase their risk.

Case presentation: In the first 3 months of the pandemic, four patients with HIV were hospitalized in our clinic because of COVID-19. The disease severity was mild in two patients with normal CD4+ T count. However, one patient with a low CD4+T count died and the other developed retinal detachment one month after discharge. The deceased patient had a malignancy.

Conclusion: In this study, the effect of the immunological status of the patients on the course of COVID-19 and the developing vascular complications was evaluated in 4 patients with HIV.

Keywords: CD4, coagulopathy, COVID-19, HIV, pandemic, retinal degenaration, SARS-CoV-2.

« Previous
Graphical Abstract

[1]
Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med 2020; 382(8): 692-4.
[http://dx.doi.org/10.1056/NEJMp2000929] [PMID: 31978293]
[2]
World Health Organization. WHO announces COVID-19 outbreak a pandemic 2020 http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic
[3]
TR; Ministry of Health. Guidelines of COVID-19 General information, epidemiology and diagnosis 2020 https://covid19.saglik.gov.tr/Eklenti/38597/0/covid-19rehberigenelbilgilerepidemiyolojivetanipdf.pdf
[4]
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
[http://dx.doi.org/10.1016/S0140-6736(20)30183-5] [PMID: 31986264]
[5]
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
[http://dx.doi.org/10.1001/jama.2020.1585] [PMID: 32031570]
[6]
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507-13.
[http://dx.doi.org/10.1016/S0140-6736(20)30211-7] [PMID: 32007143]
[7]
COVID-19 & HIV. EACS   BHIVA Statement on risk of COVID-19 for people living with HIV (PLWH) https://www.eacsociety.org/home/covid-19-and-hiv.html2020.
[8]
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382(19): 1787-99.
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[9]
Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 178 104786
[http://dx.doi.org/10.1016/j.antiviral.2020.104786] [PMID: 32251767]
[10]
Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B 2020; 10(5): 766-88.
[http://dx.doi.org/10.1016/j.apsb.2020.02.008] [PMID: 32292689]
[11]
Chien M, Anderson TK, Jockusch S, Tao C, Kumar S, Li X, et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 2020 www.biorxiv.org/content/10.1101/2020.03.18.997585v1
[12]
Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) Healthcare Personnel (EPICOS) https://clinicaltrials.gov/ct2/show/NCT04334928
[13]
Guo W, Ming F, Dong Y, et al. A Survey for COVID-19 among HIV/AIDS Patients in Two Districts of Wuhan, China Preprint research paper, Lancet https://papers.ssrn.com/sol3/papers.cfm?abstract_id=35500292020.
[14]
Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in HIV Investigators. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; 7(5): e314-6.
[http://dx.doi.org/10.1016/S2352-3018(20)30111-9] [PMID: 32304642]
[15]
Härter G, Spinner CD, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection 2020; 48(5): 681-6.
[http://dx.doi.org/10.1007/s15010-020-01438-z] [PMID: 32394344]
[16]
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130(5): 2620-9.
[http://dx.doi.org/10.1172/JCI137244] [PMID: 32217835]
[17]
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71(15): 762-8.
[http://dx.doi.org/10.1093/cid/ciaa248] [PMID: 32161940]
[18]
He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis 2005; 9(6): 323-30.
[http://dx.doi.org/10.1016/j.ijid.2004.07.014] [PMID: 16095942]
[19]
Song JW, Zhang C, Fan X, et al. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun 2020; 11(1): 3410.
[http://dx.doi.org/10.1038/s41467-020-17240-2] [PMID: 32641700]
[20]
Wang F, Nie J, Wang H, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis 2020; 221(11): 1762-9.
[http://dx.doi.org/10.1093/infdis/jiaa150] [PMID: 32227123]
[21]
Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol 2020; 11: 827.
[http://dx.doi.org/10.3389/fimmu.2020.00827] [PMID: 32425950]
[22]
Ho H, Peluso MJ, Margus C, Lopes JPM, He C, Gaisa MM, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With HumanImmunodeficiency Virus. J Infect Dis brief report 2020; 223(3): 403-8.
[23]
Ministry of Health, Turkey Guidelines of COVID-19. Adult Patient Treatment 2020 https://covid19.saglik.gov.tr/Eklenti/38355/0/covid-19rehberieriskinhastatedavisipdf.pdf
[24]
Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci 2020; 50(SI-1): 611-9.
[http://dx.doi.org/10.3906/sag-2004-145] [PMID: 32293834]
[25]
Mitjà O, Corbacho-Monné M, Ubals M, et al. BCN PEP-CoV-2 RESEARCH GROUP. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized- controlled trial. Clin Infect Dis 2020. [Online ahead of print]
[http://dx.doi.org/10.1093/cid/ciaa1009] [PMID: 32674126]
[26]
Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Eng J Med 2020. [Online ahead of print]
[http://dx.doi.org/10.1056/NEJMoa2019014]
[27]
Chen L, Zhang ZY, Fu JG, Feng ZP, Zhang SZ, Han QY, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective openlabel randomized controlled study. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.06.19.20136093]
[28]
Arshad S, Kilgore P, Chaudhry ZS, et al. Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis 2020; 97: 396-403.
[http://dx.doi.org/10.1016/j.ijid.2020.06.099] [PMID: 32623082]
[29]
Axfors C, Schmitt AM, Janiaud P, van 't Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine 2 in COVID-19: an international collaborative meta-analysis of randomized trials. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.09.16.20194571]
[30]
Catteau L, Dauby N, Montourcy M, et al. Belgian Collaborative Group on COVID-19 Hospital Surveillance. Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents 2020; 56(4) 106144.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106144] [PMID: 32853673]
[31]
COVID-19 RISK and Treatments (CORIST) Collaboration. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. Eur J Intern Med 2020; S0953-6205(20): 30335-6.
[http://dx.doi.org/10.1016/j.ejim.2020.08.019] [PMID: 32859477]
[32]
Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49(2): 215-9.
[PMID: 32391667]
[33]
Horby PW, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. medRxiv 2020.
[http://dx.doi.org/10.1101/2020.07.15.20151852v1]
[34]
Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol 2020; 12(4): 322-5.
[http://dx.doi.org/10.1093/jmcb/mjaa014] [PMID: 32236562]
[35]
Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med 2020; 173(8): 623-31.
[http://dx.doi.org/10.7326/M20-4207] [PMID: 32673060]
[36]
Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849.
[http://dx.doi.org/10.1136/bmj.m1849] [PMID: 32409561]
[37]
Chen C, Zang Y, Huang J, Yin P, Cheng Z, Wu J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial medRxiv 2020.
[http://dx.doi.org/10.1101/2020.03.17.20037432.]
[38]
Glenmark Pharmaceuticals Ltd. Glenmark announces top-line results from phase 3 clinical trial of favipiravir in patients with mild to moderate COVID-19 2020 https://www.glenmarkpharma.com/sites/default/files/Glenmark-Announces-Top-LineResults-From-Phase-3%20-Clinical.pdf
[39]
Favipiravir Observational Study Group. Preliminary Report of the Favipiravir Observational Study in Japan 2020.https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200529.pdf
[40]
Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis 2020. [Online ahead of print].
[http://dx.doi.org/10.1093/cid/ciaa1176] [PMID: 32770240]
[41]
Madelain V, Oestereich L, Graw F, et al. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res 2015; 123: 70-7.
[http://dx.doi.org/10.1016/j.antiviral.2015.08.015] [PMID: 26343011]
[42]
Geamănu Pancă A, Popa-Cherecheanu A, Marinescu B, Geamănu CD, Voinea LM. Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review. J Med Life 2014; 7(3): 322-6.
[PMID: 25408748]
[43]
Marinho PM, Marcos AAA, Romano AC, Nascimento H, Belfort R Jr. Retinal findings in patients with COVID-19. Lancet 2020; 395(10237): 1610.
[http://dx.doi.org/10.1016/S0140-6736(20)31014-X] [PMID: 32405105]
[44]
Sharifi-Razavi A, Karimi N, Rouhani N. COVID-19 and intracerebral haemorrhage: causative or coincidental? New Microbes New Infect 2020; 35
[http://dx.doi.org/10.1016/j.nmni.2020.100669] [PMID: 32322398]
[45]
Harenberg J, Favaloro E. COVID-19: progression of disease and intravascular coagulation - present status and future perspectives. Clin Chem Lab Med 2020; 58(7): 1029-36.
[http://dx.doi.org/10.1515/cclm-2020-0502] [PMID: 32406381]

Rights & Permissions Print Cite
Article Metrics
38
© 2024 Bentham Science Publishers | Privacy Policy